Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response’s main claim that RINVOQ is associated with serious infections, increased mortality, malignancy, MACE, and thrombosis is supported by the provided label excerpts (Sections 5.1–5.5, plus 2.14 and 6.1). No direct contradictions to the supplied text were identified.
Category Scores
Accurate Statements
RINVOQ use is associated with serious infections, increased mortality, malignancy, MACE, and thrombosis.
Supported by provided label excerpts: Serious infections (5.1, 2.14, 6.1), Mortality (5.2), Malignancy (5.3), MACE (5.4), Thrombosis (5.5, 6.1).
Serious infections: supported by label Sections 5.1, 2.14, and 6.1; includes serious/opportunistic infections and guidance to interrupt treatment for serious infection.
5.1 describes serious and opportunistic infections and monitoring/interrupting if serious or opportunistic infection develops; 2.14 instructs to interrupt if serious infection develops; 6.1 provides clinical trial experience including pneumonia/cellulitis and tuberculosis/opportunistic infections.
Mortality: supported by label Section 5.2 (higher all-cause mortality including sudden cardiovascular death in a postmarketing safety study with another JAK inhibitor vs TNF blockers; benefit/risk guidance).
5.2 text in the prompt.
Malignancy: supported by label Section 5.3 (malignancies including lymphomas in clinical trials; higher malignancy rates vs TNF blockers in a postmarketing safety study).
5.3 text in the prompt.
MACE: supported by label Section 5.4 (higher MACE defined as cardiovascular death, non-fatal MI, and non-fatal stroke vs TNF blockers; discontinue after MI or stroke).
5.4 text in the prompt.
Thrombosis: supported by label Sections 5.5 and 6.1 (thromboses including DVT/PE/arterial thrombosis; some serious events resulted in death; discontinuation/avoidance guidance).
5.5 text in the prompt and 6.1 clinical trial experience references.
Unsupported Statements
Contradictions
Important Omissions
The response states boxed-warning-style content was present but does not confirm whether the cited risks are specifically in an FDA boxed warning within the provided excerpts. This is not strictly incorrect for the main claim, but the 'boxed warning' determination is not supported by the provided text.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
This is an accuracy evaluation of label alignment, not an individualized risk statement or recommendation. The claims evaluated correspond to described label warnings.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The response notes 'boxed-warning-style content' / 'boxed_warning present: null' without confirmation from the provided label excerpts.
Suggested Improvement
Limit formatting assertions (e.g., boxed warning presence) to what is explicitly shown in the provided excerpt, or remove the boxed-warning implication.